Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswire Nov 13, 2026, 1:00:00 PM
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)GlobeNewswire Nov 10, 2026, 9:05:00 PM
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswire Sep 8, 2026, 12:00:00 PM